Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Adenine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 0.45 |
| ▸ | RET known ✓ | P07949 | 1/20 | 0.36 |
| ▸ | PNP known ✓ | P00491 | 1/20 | 0.32 |
| ▸ | PARP1 known ✓ | P09874 | 1/20 | 0.32 |
| ▸ | PRKCI known ✓ | P41743 | 1/20 | 0.31 |
| ▸ | PI4KA | P42356 | 7/20 | 0.48 |
| ▸ | PI4K2B | Q8TCG2 | 7/20 | 0.48 |
| ▸ | PI4K2A | Q9BTU6 | 7/20 | 0.48 |
| ▸ | PI4KB | Q9UBF8 | 7/20 | 0.48 |
| ▸ | XDH | P47989 | 2/20 | 0.45 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.38 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | RAD52 | P43351 | 1/20 | 0.34 |
| ▸ | GDA | Q9Y2T3 | 2/20 | 0.32 |
| ▸ | BTK | Q06187 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Adenine SCHEMBL2428538 | 1.00 | PI4KA (0.48) | PI4KAPI4K2BPI4K2API4KBXDH | |
| Adenine SCHEMBL680904 | 0.98 | PI4KA (0.50) | PI4KAPI4K2BPI4K2API4KBXDH | |
| Adenine SCHEMBL2772644 | 0.98 | PI4KA (0.47) | PI4KAPI4K2BPI4K2API4KBXDH | |
| Adenine SCHEMBL7204509 | 0.98 | PI4KA (0.50) | PI4KAPI4K2BPI4K2API4KBXDH | |
| Adenine SCHEMBL2895675 | 0.98 | PI4KA (0.47) | PI4KAPI4K2BPI4K2API4KBXDH | |
| Adenine SCHEMBL3416954 | 0.96 | PI4KA (0.48) | PI4KAPI4K2BPI4K2API4KBXDH | |
| Adenine SCHEMBL3413247 | 0.96 | PI4KA (0.48) | PI4KAPI4K2BPI4K2API4KBXDH | |
| Adenine SCHEMBL8110 | 0.96 | PI4KA (0.48) | PI4KAPI4K2BPI4K2API4KBXDH | |
| Adenine SCHEMBL5601016 | 0.93 | PI4KA (0.47) | PI4KAPI4K2BPI4K2API4KBXDH | |
| Adenine SCHEMBL691914 | 0.93 | PI4KA (0.47) | PI4KAPI4K2BPI4K2API4KBXDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2542591-B1 | SILYL-DERIVATIVES OF POLYSACCHARIDES | SILDEHA SWISS SA (CH) | 2019-10-16 | — | — | EP | disclosed |
| US-9598505-B2 | Silyl-derivatives of polysaccharides | SILDEHA SIXASS S.A. (CH) | 2017-03-21 | — | — | US | disclosed |
| EP-1525224-B1 | HYALURONIC ACID DERIVATIVES | SILDEHA SWISS S A (CH) | 2015-07-01 | — | — | EP | disclosed |
| US-20130029934-A1 | SILYL-DERIVATIVES OF POLYSACCHARIDES | SILDEHA SWISS S.A. (CH) | 2013-01-31 | — | — | US | disclosed |
| EP-2542591-A2 | SILYL-DERIVATIVES OF POLYSACCHARIDES | Jasper LLC (US) | 2013-01-09 | — | — | EP | disclosed |
| WO-2011107866-A2 | SILYL-DERIVATIVES OF POLYSACCHARIDES | JASPER LLC (US) | 2011-09-09 | — | — | WO | disclosed |
| US-7662800-B2 | Hyaluronic acid derivatives | JASPER LTD. LIABILITY CO. (US) | 2010-02-16 | — | — | US | disclosed |
| US-20050239727-A1 | for use in cosmetics, drugs | SILDEHA SWISS SA (CH) | 2005-10-27 | — | — | US | disclosed |
| EP-1525224-A1 | HYALURONIC ACID DERIVATIVES | Jasper Ltd. Liability Co. (US) | 2005-04-27 | — | — | EP | disclosed |
| WO-2004013182-A1 | HYALURONIC ACID DERIVATIVES | JASPER LTD LIABILITY CO. (US) | 2004-02-12 | — | — | WO | disclosed |
| US-4216317-A | Process for preparing adenine | MERCK & CO., INC. (US) | 1980-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239727-A1 | for use in cosmetics, drugs | HINT1, NUDT1, NNT | DRD3 1651/4885RET 2463/4885PNP 5/4885 |
| US-20130029934-A1 | SILYL-DERIVATIVES OF POLYSACCHARIDES | FUT5, CSGALNACT1, FUT6 | DRD3 2128/4885RET 4850/4885PNP 4095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.